Senior Software Engineer

Tasman Therapeutics announces strategic partnership with Osmind to advance R-107 for depressive disorders. Aug 12, 2026, 08:00 ET * Collaboration will leverage Osmind's real-world evidence platform and national clinical network to support Tasman's pivotal Phase 3 ROCKET program, launch readiness, and growth. * R-107 is an investigational oral extended-release ketamine product designed for at-home administration for difficult to treat depressive disorders. SAN FRANCISCO, Aug. 12, 2026 /PRNewswire/ - Tasman Therapeutics today announced a multi-year strategic partnership with Osmind, the market leader in technology and real-world evidence for psychiatry, to support its R-107 Ketamine program. The partnership will support Tasman's ROCKET Phase 3 pivotal program and lay the groundwork for a highly differentiated technology and data-enabled commercialization strategy for R-107's potential future launch. Osmind powers the largest network of independent psychiatry practices in the United States that offer next-generation treatments for treatment-resistant depression, including intravenous ketamine, intranasal esketamine, and other related therapies. Through its proprietary electronic health record and artificial intelligence platform, Osmind has built the world's largest real-world dataset of patients treated with rapid-acting psychopharmacologic drugs, positioning it as the leading research and commercial partner for companies developing novel treatments in this therapeutic class. In the near term, Tasman will leverage Osmind's real-world data and clinical network to support the design and execution of the ROCKET Phase 3 program and pipeline expansion. This includes helping optimize trial design, safety characterization, and regulatory strategy, as well as clinical trial site identification and awareness support across Osmind's national network of interventional psychiatry practices. Looking ahead to R-107's potential approval and launch, Osmind will accelerate Tasman's commercialization through unique, technology-enabled infrastructure optimized with data and artificial intelligence for patient care and compliance. This differentiated approach will encompass longitudinal evidence generation, a consumer-facing patient app, a longitudinal data registry, and a clinician network model supporting both in-person and at-home care. "As we advance R-107 through Phase 3 and toward what we believe can be the first and only oral, at-home monotherapy for treatment-resistant depression, having a strategic partner with Osmind's data, technology footprint, clinical network, and operational and artificial intelligence expertise gives us a meaningful advantage - both in how we execute our trials and in how we think about safely bringing R-107 to patients at scale in a truly innovative way," said Dan Browne, CEO of Tasman Therapeutics. "Tasman is developing what we believe will become one of the most important new treatments in psychiatry. An oral, effective, safe, at-home treatment option for depression would be exactly the kind of innovation patients need," said Jimmy Qian, Co-founder and President of Osmind. "We've spent years building the infrastructure, technology, datasets, and clinical relationships that sit at the center of the treatment landscape for rapid-acting psychopharmacologic drugs. We look forward to leveraging these assets to support Tasman through Phase 3 today to the technology and care delivery model that will define how patients experience R-107 tomorrow." About R-107 R-107 is an investigational, Phase 3, extended-release oral ketamine tablet being developed as a monotherapy for treatment-resistant depression. R-107 has been studied clinically in Phase 2 and long-term, open-label safety trials in Australia and New Zealand since 2021. In Tasman's BEDROC Phase 2 study, published in Nature Medicine, R-107 demonstrated a rapid onset and durable, statistically significant improvement in TRD symptoms compared to placebo, with a differentiated tolerability profile designed to enable safe self-administration at home. Tasman's pivotal Phase 3 ROCKET program is underway, with topline data anticipated in 2027. About Tasman Therapeutics Tasman Therapeutics, Inc. is a clinical-stage biopharmaceutical company and U.S. affiliate of Douglas Pharmaceuticals Ltd., New Zealand's largest pharmaceutical company, developing novel treatments for neuropsychiatric disorders. Tasman's lead candidate, R-107, is an extended-release oral ketamine tablet in Phase 3 development for treatment-resistant depression. Headquartered in San Francisco, Tasman is led by an experienced team with a track record of bringing first-in-class treatments to market. For more information, visit www.tasmantherapeutics.com. About Osmind Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind's psychiatry-tailored software and services, used by leading psychiatry practices across the U.S., help improve patient outcomes while driving practice success. Osmind's network of over 1,000 practices comprises the country's largest network of interventional psychiatry practices. Osmind's practice network, point-of-care software, and real-world data support life sciences companies in developing and scaling access to cutting-edge treatments. Learn more at osmind.org. SOURCE Tasman Therapeutics

Compass Pathways collaborates with Osmind to advance independent clinic readiness for psychedelic treatments. LONDON & NEW YORK-(BUSINESS WIRE)- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind's network of over 1,000 clinics comprises one of the country's largest network of interventional psychiatry practices. Its psychiatry-tailored software and services are designed to enable clinicians to offer innovative psychiatric treatments sustainably, without giving up independence. Together, Compass and Osmind aim to better understand the operational, clinical, and infrastructure needs of independent psychiatry practices, and to help inform scalable, real-world pathways for the potential delivery of psychedelic treatments in community-based settings. "A core focus for Compass is to ensure that COMP360 can be delivered responsibly, safely, and effectively in the real-world settings where patients receive care," said Dr. Steve Levine, Chief Patient Officer at Compass Pathways. "Through this collaboration, we will support Osmind and their network to prepare for the potential delivery of psychedelic treatments, learning alongside them to better understand the needs of independent practices. Together, we aim to inform scalable, patient-centered care models that uphold the highest standards of quality as clinics nationwide prepare for the potential future delivery of COMP360." "Independent psychiatry practices are where the vast majority of patients receive their care - but they've historically been left behind when it comes to adopting innovative treatments because the operational burden is simply too high," said Jimmy Qian, Co-Founder and President of Osmind. "This collaboration combines Osmind's deep understanding of practice management with Compass' scientific expertise, helping to inform how breakthrough psychedelic treatments can be integrated into everyday practice in a way that aligns patient safety, clinical excellence, access, and practice success." About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Novumpr is motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. Novumpr is pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Compass is headquartered in London, UK, with offices in New York in the US. Novumpr envision a world where mental health means not just the absence of illness but the ability to thrive. Forward-looking statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as "may", "might", "will", "could", "would", "should", "expect", "intend", "plan", "objective", "anticipate", "believe", "contemplate", "estimate", "predict", "potential", "continue" and "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding its expectations regarding its business strategy and goals; its expectations regarding the safety or efficacy of its investigational COMP360 psilocybin treatment, including as a treatment of TRD or PTSD; the potential for the pivotal phase 3 program in TRD to support regulatory filings and approvals on an accelerated basis or at all; its ability to obtain FDA approval and adequate coverage and reimbursement for COMP360 psilocybin treatment; its expectations regarding potential commercial launch timelines and its commercial readiness; and its plans, expectations and ability to achieve the goals related to this research collaboration agreement. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass's control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore its clinical trials may be delayed or terminated and may be more costly than expected; its need for additional funding to achieve its business goals; its efforts to obtain marketing approval from FDA or regulatory authorities in any other jurisdiction for its investigational COMP360 psilocybin treatment may be unsuccessful; its efforts to commercialize and obtain coverage and reimbursement for its investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; the risk that this research collaboration with Osmind will not continue or will not achieve the expected benefits; uncertainties regarding the ability to develop a scalable and practical delivery model for COMP360 psilocybin treatment; market adoption and access to COMP360 psilocybin treatment, if approved, may be limited; and those risks and uncertainties described under the heading "Risk Factors" in Compass's most recent annual report on Form 10-K or quarterly report on Form 10-Q, the prospectus supplement related to the proposed public offering we plan to file and in other reports we have filed with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at http://www.sec.gov. Except as required by law, Compass disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Compass's current expectations and speak only as of the date hereof.